marketcap
Facebook
X
TelegramAnnual report 2022
added 03-29-2023
Chembio Diagnostics Market Cap 2011-2025 | CEMI
As of November 11, 2025 Chembio Diagnostics has a market cap of $ 16.8 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.6 M | 27.7 M | 132 M | 67.8 M | 101 M | 102 M | 57.9 M | 47 M | 35.6 M | 32.8 M | 41.9 M | 29.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 12.6 M | 57.4 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | $ 0.33 | -6.23 % | $ 30.6 M |  Germany |
 |
Fluidigm Corporation
FLDM
|
481 M | $ 3.75 | 1.08 % | $ 308 M |  USA |
 |
Global Cord Blood Corporation
CO
|
243 M | $ 2.99 | - | $ 399 M |  China |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | $ 21.99 | - | $ 562 M |  Britain |
 |
Genetron Holdings Limited
GTH
|
1.54 B | $ 4.03 | 0.12 % | $ 80.1 M | China |
 |
Meridian Bioscience
VIVO
|
1.35 B | $ 33.97 | - | $ 1.49 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | $ 0.48 | -20.0 % | $ 1.06 M | USA |
 |
Quotient Limited
QTNT
|
183 M | $ 0.32 | -11.32 % | $ 1.1 M |  Schweiz |
 |
OPKO Health
OPK
|
1.21 B | $ 1.32 | -1.4 % | $ 916 M | USA |
 |
Pacific Biosciences of California
PACB
|
1.41 B | $ 1.76 | -0.28 % | $ 446 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | $ 165.21 | - | $ 10.7 B | USA |
 |
Heska Corporation
HSKA
|
844 M | $ 119.99 | - | $ 1.31 B | USA |
 |
Bioventus
BVS
|
351 M | $ 7.48 | 0.4 % | $ 469 M | USA |
 |
Thermo Fisher Scientific
TMO
|
206 B | $ 577.56 | 0.9 % | $ 221 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | $ 0.17 | -34.28 % | $ 263 K |  Israel |
 |
Biocept
BIOC
|
5.93 M | $ 0.43 | -13.05 % | $ 7.29 M | USA |
 |
Twist Bioscience Corporation
TWST
|
2.46 B | $ 31.02 | 2.48 % | $ 1.8 B | USA |
 |
Syneos Health
SYNH
|
9.35 B | $ 42.98 | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | $ 0.09 | - | $ 21.2 M | USA |
 |
DermTech
DMTK
|
42.4 M | $ 0.09 | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
75.1 M | $ 0.29 | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
709 M | $ 34.72 | 5.07 % | $ 964 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 12.88 | 3.04 % | $ 365 M | Israel |
 |
PerkinElmer
PKI
|
14.1 B | $ 115.24 | -0.91 % | $ 14.7 B | USA |
 |
OpGen
OPGN
|
9.12 M | $ 1.96 | -16.95 % | $ 1.54 M | USA |
 |
DexCom
DXCM
|
48.8 B | $ 54.77 | -0.42 % | $ 21.1 B | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | $ 2.12 | -2.3 % | $ 19.4 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 12.19 | 3.57 % | $ 131 M | China |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 6.38 | -0.39 % | $ 1.38 B | USA |
 |
Danaher Corporation
DHR
|
152 B | $ 211.31 | 0.65 % | $ 154 B | USA |
 |
Quidel Corporation
QDEL
|
10.6 B | $ 19.71 | -3.14 % | $ 830 M | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.46 | - | $ 5.65 M | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 27.27 | 3.45 % | $ 825 M | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | $ 2.67 | -1.84 % | $ 15.3 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | $ 0.77 | - | $ 7.1 B |  Australia |
 |
Renalytix AI plc
RNLX
|
22.7 M | $ 0.21 | 5.66 % | $ 22.7 M | Britain |
 |
Myriad Genetics
MYGN
|
973 M | $ 6.49 | 3.02 % | $ 588 M | USA |
 |
Trinity Biotech plc
TRIB
|
120 M | $ 0.93 | -1.39 % | $ 61.9 M |  Irlanda |
 |
Medpace Holdings
MEDP
|
10.2 B | $ 602.17 | 2.21 % | $ 18.6 B | USA |
 |
IQVIA Holdings
IQV
|
35.7 B | $ 214.01 | 1.69 % | $ 38.8 B | USA |
 |
CareDx, Inc
CDNA
|
521 M | $ 16.54 | 5.86 % | $ 889 M | USA |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 16.25 | 4.23 % | $ 99.4 M | Israel |
|
Biodesix
BDSX
|
92.1 M | $ 7.46 | -3.56 % | $ 967 M | USA |
 |
T2 Biosystems
TTOO
|
7.78 M | $ 0.12 | -39.35 % | $ 313 K | USA |
 |
Exagen
XGN
|
31.3 M | $ 9.51 | -0.52 % | $ 168 M | USA |
 |
Guardant Health
GH
|
5.84 B | $ 97.65 | 0.96 % | $ 12 B | USA |
 |
Agilent Technologies
A
|
42 B | $ 146.92 | 0.12 % | $ 44.7 B | USA |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 0.39 | -3.18 % | $ 11.4 M | USA |
 |
Lantheus Holdings
LNTH
|
6.47 B | $ 50.52 | -1.08 % | $ 3.5 B | USA |